Sponsor content
330 result(s) found, displaying 11 to 20
-
Prescription medicine registrationActive ingredients: trastuzumab deruxtecan.
-
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for KAVIGALE, sipavibart, 300 mg in 2 mL (150 mg/mL), Solution for injection/infusion vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for DATROWAY datopotamab deruxtecan 100 mg powder for injection vial.
-
Sep-2025Prescription medicine evaluationActive ingredient: tezepelumab.
-
Sep-2025Prescription medicine evaluationActive ingredient: budesonide, formoterol fumarate dihydrate, glycopyrronium bromide.
-
Sep-2025Prescription medicine evaluationActive ingredient: benralizumab.
-
Australian public assessment report (AusPar)DATROWAY (datopotamab deruxtecan) as a monotherapy is for the treatment of adult patients with unresectable or metastatic, hormone receptor (HR)-positive, HER2-negative breast cancer who have received endocrine therapy and at least one additional systemic therapy in the locally advanced or metastatic setting.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Tezspire tezepelumab 210 mg in 1.91mL solution for Injection prefilled pen.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for Tezspire, tezepelumab 210 mg in 1.91mL solution for Injection prefilled syringe.